Embecta Q3: Revenue Drops 8%, Margins Shrink, but Owen Mumford Acquisition Closes
EMBC sits 68% above its 52-week low of $2.77 on elevated volume (2.0× avg).
Summary
Embecta's Q3 net income fell 54% YoY to $21.1M, as revenue slid 8% to $271.7M. Gross margins compressed to 56.4%. The Owen Mumford acquisition contributed $13.8M in revenue. The company also amended its credit agreement, reducing its revolver and adding tighter covenants.
Key Events · Earnings and Guidance · EMBC
-
Q3 Earnings Miss
Net income came in at $21.1M, a 54% drop from $45.5M in the prior-year quarter. Revenue fell 8.1% to $271.7M, pressured by unfavorable price and volume changes.
-
Gross Margin Compression
Gross profit margin narrowed to 56.4% from 66.7% a year ago, primarily reflecting the Owen Mumford acquisition and profit-in-inventory adjustments.
-
Owen Mumford Acquisition Impact
The acquisition added $13.8M in revenue but also brought higher costs, including $11.3M in acquisition-related expenses and an increased cost of products sold.
-
Credit Agreement Amendment
On August 6, 2026, the company amended its credit agreement, cutting the revolving credit facility from $500M to $310M and extending $210M of commitments to December 2028, with tighter financial covenants.
Analysis · EMBC · Industrial Applications And Services
A sharp profitability decline marks Embecta's Q3, with net income tumbling 54% year-over-year on an 8% revenue contraction. The Owen Mumford acquisition and an unfavorable product mix drove significant gross margin compression. Adding to the pressure, a credit agreement amendment shrinks the revolving facility and tightens covenants, hinting at liquidity strains. A securities class action lawsuit introduces further legal risk, collectively painting a challenging picture for the diabetes device maker.
At the time of this filing, EMBC was trading at $4.66 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $276.2M. The 52-week trading range was $2.77 to $15.55. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.